All Stories

  1. Stratification in small randomised clinical trials and analysis of covariance: Some simple theory and recommendations

    Article • Statistical Methods in Medical Research, August 2026, SAGE Publications

    Martin Posch

  2. Statistical Innovation for Integrated Evidence in Medical Product Development

    Article • Statistics in Biopharmaceutical Research, July 2026, Taylor & Francis

    Martin Posch

  3. Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control

    Article • Pharmaceutical Statistics, June 2026, Wiley

    Martin Posch

  4. On the Inclusion of Non‐Concurrent Controls in Platform Trials With an Interim Analysis

    Article • Statistics in Medicine, May 2026, Wiley

    Martin Posch

  5. Graph Based, Adaptive, Multiarm, Multiple Endpoint, Two‐Stage Designs

    Article • Statistics in Medicine, December 2025, Wiley

    Martin Posch

  6. Design Considerations for a Phase II Platform Trial in Major Depressive Disorder

    Article • Pharmaceutical Statistics, August 2025, Wiley

    Martin Posch

  7. Treatment-Control Comparisons in Platform Trials Including Non-Concurrent Controls

    Article • Statistics in Biopharmaceutical Research, June 2025, Taylor & Francis

    Martin Posch

  8. Statistical Modeling to Adjust for Time Trends in Adaptive Platform Trials Utilizing Non‐Concurrent Controls

    Article • Biometrical Journal, June 2025, Wiley

    Martin Posch

  9. Classification grid and evidence matrix for evaluating digital medical devices under the European union landscape

    Article • npj Digital Medicine, May 2025, Springer Science + Business Media

    Martin Posch

  10. Transforming the evidence landscape in mental health with platform trials

    Article • Nature Mental Health, March 2025, Springer Science + Business Media

    Martin Posch

  11. A Comparison of Statistical Methods for Time‐To‐Event Analyses in Randomized Controlled Trials Under Non‐Proportional Hazards

    Article • Statistics in Medicine, February 2025, Wiley

    Martin Posch

  12. Efficiency of multivariate tests in trials in progressive supranuclear palsy

    Article • Scientific Reports, October 2024, Springer Science + Business Media

    Martin Posch

  13. Rejoinder

    Article • Statistics in Biopharmaceutical Research, October 2024, Taylor & Francis

    Martin Posch

  14. Resuscitative endovascular balloon occlusion of the aorta for trauma patients with uncontrolled hemorrhage: a retrospective target trial emulation (the AT-REBOA target trial)

    Article • European Journal of Emergency Medicine, September 2024, Wolters Kluwer Health

    Martin Posch

  15. Intensive care unit caseload and workload and their association with outcomes in critically unwell patients: a large registry-based cohort analysis

    Article • Critical Care, September 2024, Springer Science + Business Media

    Martin Posch

  16. Evaluation of the Fill-it-up-design to use historical control data in randomized clinical trials with two arm parallel group design

    Article • BMC Medical Research Methodology, September 2024, Springer Science + Business Media

    Martin Posch

  17. A low-noise always-on interference-robust 125kHz key fob wake-up receiver

    Article • September 2024, Institute of Electrical & Electronics Engineers (IEEE)

    Martin Posch

  18. A general consonance principle for closure tests based on p-values

    Article • Statistical Methods in Medical Research, September 2024, SAGE Publications

    Martin Posch

  19. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)

    Article • International Journal of Infectious Diseases, September 2024, Elsevier

    Martin Posch

  20. Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory

    Article • Movement Disorders, August 2024, Wiley

    Martin Posch

  21. Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper

    Article • Infection, July 2024, Springer Science + Business Media

    Martin Posch

  22. Methods for non-proportional hazards in clinical trials: A systematic review

    Article • Statistical Methods in Medical Research, April 2024, SAGE Publications

    Martin Posch

  23. Regulatory Issues of Platform Trials: Learnings from EU‐PEARL

    Article • Clinical Pharmacology & Therapeutics, March 2024, Wiley

    Martin Posch

  24. Optimal allocation strategies in platform trials with continuous endpoints

    Article • Statistical Methods in Medical Research, March 2024, SAGE Publications

    Martin Posch

  25. Simultaneous inference procedures for the comparison of multiple characteristics of two survival functions

    Article • Statistical Methods in Medical Research, March 2024, SAGE Publications

    Martin Posch

  26. Red blood cell transfusion-related dynamics of extracellular vesicles in intensive care patients: a prospective subanalysis

    Article • Scientific Reports, January 2024, Springer Science + Business Media

    Martin Posch

  27. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

    Article • EClinicalMedicine, January 2024, Elsevier

    Martin Posch, Dr Joan Genesca

  28. Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

    Article • Statistics in Biopharmaceutical Research, November 2023, Taylor & Francis

    Martin Posch

  29. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1)

    Article • Vaccine, November 2023, Elsevier

    Martin Posch

  30. The impact of religion on changes in end-of-life practices in European intensive care units: a comparative analysis over 16 years

    Article • Intensive Care Medicine, October 2023, Springer Science + Business Media

    Martin Posch

  31. Statistical Considerations in Pediatric Cancer Trials: Report of American Statistical Association Biopharmaceutical Section Open Forum Discussions

    Article • Statistics in Biopharmaceutical Research, September 2023, Taylor & Francis

    Martin Posch

  32. Are early post‐discharge physician contacts associated with 30‐day psychiatric re‐hospitalisation? A nationwide claims data based retrospective cohort study in Austria free of immortal time bias

    Article • International Journal of Methods in Psychiatric Research, August 2023, Wiley

    Martin Posch

  33. Comparing maximum diameter and volume when assessing the growth of small abdominal aortic aneurysms using longitudinal CTA data: cohort study

    Article • International Journal of Surgery, July 2023, Wolters Kluwer Health

    Martin Posch

  34. NCC: An R-package for analysis and simulation of platform trials with non-concurrent controls

    Article • SoftwareX, July 2023, Elsevier

    Martin Posch, Peter Jacko

  35. Vaccine Development during a Pandemic: General Lessons for Clinical Trial Design

    Article • Statistics in Biopharmaceutical Research, June 2023, Taylor & Francis

    Martin Posch

  36. On the use of non-concurrent controls in platform trials: a scoping review

    Article • Trials, June 2023, Springer Science + Business Media

    Martin Posch

  37. Nationwide analysis of hospital admissions and outcomes of patients with SARS-CoV-2 infection in Austria in 2020 and 2021

    Article • Scientific Reports, May 2023, Springer Science + Business Media

    Martin Posch

  38. Online error rate control for platform trials

    Article • Statistics in Medicine, April 2023, Wiley

    Martin Posch

  39. Red blood cell transfusion-related eicosanoid profiles in intensive care patients—A prospective, observational feasibility study

    Article • Frontiers in Physiology, March 2023, Frontiers

    Martin Posch

  40. Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials

    Article • Alimentary Pharmacology & Therapeutics, March 2023, Wiley

    Martin Posch

  41. Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators

    Article • Statistics in Biopharmaceutical Research, February 2023, Taylor & Francis

    Martin Posch

  42. Implementing clinical trial data sharing requires training a new generation of biomedical researchers

    Article • Nature Medicine, February 2023, Springer Science + Business Media

    Martin Posch, Dr. Thomas Debray

  43. Association of immediate versus delayed extubation of patients admitted to intensive care units postoperatively and outcomes: A retrospective study

    Article • PLOS One, January 2023, PLOS

    Paul Zajic, Martin Posch

  44. Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)

    Article • January 2023, Elsevier

    Martin Posch

  45. Immunogenicity, Reactogenicity and Safety of a Second Booster with BNT162b2 or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1-AGED Part B)

    Article • January 2023, Elsevier

    Martin Posch

  46. Optimal designs for the development of personalized treatment rules

    Article • Scandinavian Journal of Statistics, December 2022, Wiley

    Martin Posch

  47. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

    Article • Trials, October 2022, Springer Science + Business Media

    Martin Posch

  48. Online control of the False Discovery Rate in group-sequential platform trials

    Article • Statistical Methods in Medical Research, October 2022, SAGE Publications

    Martin Posch

  49. Impact of adaptive filtering on power and false discovery rate in RNA-seq experiments

    Article • BMC Bioinformatics, September 2022, Springer Science + Business Media

    Martin Posch

  50. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment

    Article • Biostatistics, September 2022, Oxford University Press (OUP)

    Martin Posch

  51. Cancer Clinical Trials beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

    Article • Statistics in Biopharmaceutical Research, September 2022, Taylor & Francis

    Martin Posch

  52. STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACC...

    Article • August 2022, Research Square

    Martin Posch

  53. Commentary: Two approaches to analyze platform trials incorporating non-concurrent controls with a common assumption

    Article • Clinical Trials, August 2022, SAGE Publications

    Martin Posch

  54. On model-based time trend adjustments in platform trials with non-concurrent controls

    Article • BMC Medical Research Methodology, August 2022, Springer Science + Business Media

    Martin Posch, Peter Jacko

  55. Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials”

    Article • Statistics in Biopharmaceutical Research, August 2022, Taylor & Francis

    Martin Posch

  56. Rationale for the update algorithm of the graphical approach to sequentially rejective multiple test procedures

    Article • Pharmaceutical Statistics, July 2022, Wiley

    Martin Posch

  57. Incidence and Outcomes of Cardiopulmonary Resuscitation in ICUs: Retrospective Cohort Analysis

    Article • Critical Care Medicine, June 2022, Wolters Kluwer Health

    Martin Posch

  58. Validation of bedside ultrasound to predict lumbar muscle area in the computed tomography in 200 non-critically ill patients: The USVALID prospective study

    Article • Clinical Nutrition, April 2022, Elsevier

    Martin Posch

  59. Estimands and Complex Innovative Designs

    Article • Clinical Pharmacology & Therapeutics, March 2022, Wiley

    Martin Posch

  60. Statistical advising: Professional development opportunities for the biostatistician

    Article • Statistics in Medicine, February 2022, Wiley

    Martin Posch

  61. Sex Differences in Kidney Transplantation: Austria and the United States, 1978–2018

    Article • Frontiers in Medicine, January 2022, Frontiers

    Martin Posch

  62. Platform trials and the future of evaluating therapeutic behavioural interventions

    Article • Nature Reviews Psychology, January 2022, Springer Science + Business Media

    Martin Posch

  63. Assessment of tumour-agnostic therapies in basket trials

    Article • The Lancet Oncology, January 2022, Elsevier

    Martin Posch

  64. Robust group sequential designs for trials with survival endpoints and delayed response

    Article • Biometrical Journal, December 2021, Wiley

    Martin Posch

  65. Statistical Issues and Challenges in Clinical Trials for COVID-19 Treatments, Vaccines, Medical Devices and Diagnostics

    Article • Statistics in Biopharmaceutical Research, December 2021, Taylor & Francis

    Martin Posch, Dr Toshimitsu Hamasaki

  66. Growth prediction model for abdominal aortic aneurysms

    Article • BJS, November 2021, Oxford University Press (OUP)

    Martin Posch

  67. Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study

    Article • The Lancet Respiratory Medicine, October 2021, Elsevier

    Martin Posch

  68. An international comparison of age and sex dependency of COVID-19 deaths in 2020: a descriptive analysis

    Article • Scientific Reports, September 2021, Springer Science + Business Media

    Martin Posch

  69. Analysis of the specificity of a COVID-19 antigen test in the Slovak mass testing program

    Article • PLOS One, July 2021, PLOS

    Martin Posch

  70. Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

    Article • Statistics in Biopharmaceutical Research, July 2021, Taylor & Francis

    Martin Posch

  71. How reliably can ultrasound help determine muscle and adipose tissue thickness in clinical settings? An assessment of intra- and inter-examiner reliability in the USVALID study

    Article • European Journal of Clinical Nutrition, July 2021, Springer Science + Business Media

    Martin Posch

  72. Association of Acute Kidney Injury Receiving Kidney Replacement Therapy With Prognosis of Critically Ill Patients With and Without Cancer: A Retrospective Study

    Article • Critical Care Medicine, June 2021, Wolters Kluwer Health

    Martin Posch

  73. The impact of the SARS‐CoV‐2 pandemic on the ongoing prospective, international, multicentre observational study assessing the preoperative anaemia prevalence in surgical patients (ALICE‐trial)

    Article • Transfusion Medicine, May 2021, Wiley

    Martin Posch

  74. Evaluation and calibration of SAPS 3 in patients with COVID-19 admitted to intensive care units

    Article • Intensive Care Medicine, May 2021, Springer Science + Business Media

    Martin Posch

  75. Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion

    Article • Statistics in Biopharmaceutical Research, April 2021, Taylor & Francis

    Martin Posch

  76. The use of external controls: To what extent can it currently be recommended?

    Article • Pharmaceutical Statistics, April 2021, Wiley

    Martin Posch

  77. Optimizing subgroup selection in two‐stage adaptive enrichment and umbrella designs

    Article • Statistics in Medicine, March 2021, Wiley

    Martin Posch

  78. Collaborative Platform Trials to Fight COVID‐19: Methodological and Regulatory Considerations for a Better Societal Outcome

    Article • Clinical Pharmacology & Therapeutics, March 2021, Wiley

    Martin Posch

  79. An international comparison of age and sex dependency of COVID-19 Deaths in 2020 - a descriptive analysis

    Article • March 2021, Cold Spring Harbor Laboratory Press

    Martin Posch

  80. Factors associated with physician decision making on withholding cardiopulmonary resuscitation in prehospital medicine

    Article • Scientific Reports, March 2021, Springer Science + Business Media

    Martin Posch

  81. Analysis of the specificity of the SD Biosensor Standard Q Ag-Test based on Slovak mass testing data

    Article • December 2020, Cold Spring Harbor Laboratory Press

    Martin Posch

  82. Are p-values Useful to Judge the Evidence Against the Null Hypotheses in Complex Clinical Trials? A Comment on ”The Role of p-values in Judging the Strength of Evidence and Realistic Replication Expectations”

    Article • Statistics in Biopharmaceutical Research, November 2020, Taylor & Francis

    Martin Posch

  83. Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic

    Article • Statistics in Biopharmaceutical Research, October 2020, Taylor & Francis

    Martin Posch, Dr Toshimitsu Hamasaki

  84. Efficient two-stage sequential arrays of proof of concept studies for pharmaceutical portfolios

    Article • Statistical Methods in Medical Research, September 2020, SAGE Publications

    Martin Posch

  85. Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology

    Article • Pharmaceutical Statistics, August 2020, Wiley

    Martin Posch

  86. Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19

    Article • Statistics in Biopharmaceutical Research, July 2020, Taylor & Francis

    Martin Posch

  87. Analysis of Austrian COVID-19 deaths by age and sex

    Article • Wiener klinische Wochenschrift, July 2020, Springer Science + Business Media

    Martin Posch

  88. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review

    Article • Clinical Therapeutics, July 2020, Elsevier

    Martin Posch

  89. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials

    Article • Clinical Pharmacology & Therapeutics, April 2020, Wiley

    Martin Posch

  90. Optimized multiple testing procedures for nested sub-populations based on a continuous biomarker

    Article • Statistical Methods in Medical Research, March 2020, SAGE Publications

    Martin Posch

  91. Testing Procedures for Claiming Success on at Least k Out of m Hypotheses with an Application to Biosimilar Development

    Article • Statistics in Biopharmaceutical Research, March 2020, Taylor & Francis

    Martin Posch

  92. A critical review of graphics for subgroup analyses in clinical trials

    Article • Pharmaceutical Statistics, March 2020, Wiley

    Martin Posch

  93. A multiple comparison procedure for dose‐finding trials with subpopulations

    Article • Biometrical Journal, September 2019, Wiley

    Martin Posch

  94. Simultaneous inference for multiple marginal generalized estimating equation models

    Article • Statistical Methods in Medical Research, September 2019, SAGE Publications

    Martin Posch

  95. Time of Day and its Association with Risk of Death and Chance of Discharge in Critically Ill Patients: A Retrospective Study

    Article • Scientific Reports, August 2019, Springer Science + Business Media

    Martin Posch

  96. Quantitative approaches underpinning decision making

    Article • Biometrical Journal, July 2019, Wiley

    Martin Posch

  97. Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873

    Article • Pharmaceutical Statistics, March 2019, Wiley

    Martin Posch

  98. Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations

    Article • Pharmaceutical Statistics, January 2019, Wiley

    Martin Posch

  99. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency

    Article • Trials, November 2018, Springer Science + Business Media

    Martin Posch

  100. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties

    Article • Orphanet Journal of Rare Diseases, November 2018, Springer Science + Business Media

    Martin Posch

  101. Applicability and added value of novel methods to improve drug development in rare diseases

    Article • Orphanet Journal of Rare Diseases, November 2018, Springer Science + Business Media

    Martin Posch

  102. Recent advances in methodology for clinical trials in small populations: the InSPiRe project

    Article • Orphanet Journal of Rare Diseases, October 2018, Springer Science + Business Media

    Martin Posch

  103. Subgroup identification in clinical trials via the predicted individual treatment effect

    Article • PLOS One, October 2018, PLOS

    Martin Posch

  104. Design and estimation in clinical trials with subpopulation selection

    Article • Statistics in Medicine, August 2018, Wiley

    Martin Posch

  105. A proposal for a new PhD level curriculum on quantitative methods for drug development

    Article • Pharmaceutical Statistics, July 2018, Wiley

    Martin Posch

  106. Methods for the analysis of multiple endpoints in small populations: A review

    Article • Journal of Biopharmaceutical Statistics, July 2018, Taylor & Francis

    Martin Posch

  107. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup

    Article • Statistics in Medicine, June 2018, Wiley

    Martin Posch

  108. Statistical analysis of Goal Attainment Scaling endpoints in randomised trials

    Article • Statistical Methods in Medical Research, June 2018, SAGE Publications

    Martin Posch

  109. Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker

    Article • Statistical Methods in Medical Research, June 2018, SAGE Publications

    Martin Posch

  110. Optimal exact tests for multiple binary endpoints

    Article • Computational Statistics & Data Analysis, June 2018, Elsevier

    Martin Posch

  111. Value of information methods to design a clinical trial in a small population to optimise a health economic utility function

    Article • BMC Medical Research Methodology, February 2018, Springer Science + Business Media

    Martin Posch

  112. Marketing authorisation of orphan medicines in Europe from 2000 to 2013

    Article • Drug Discovery Today, February 2018, Elsevier

    Martin Posch

  113. Approaches to sample size calculation for clinical trials in rare diseases

    Article • Pharmaceutical Statistics, January 2018, Wiley

    Martin Posch

  114. Optimized adaptive enrichment designs

    Article • Statistical Methods in Medical Research, December 2017, SAGE Publications

    Martin Posch

  115. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection

    Article • Journal of the American Society of Nephrology, December 2017, American Society of Nephrology

    Martin Posch

  116. Weekends affect mortality risk and chance of discharge in critically ill patients: a retrospective study in the Austrian registry for intensive care

    Article • Critical Care, September 2017, Springer Science + Business Media

    Martin Posch

  117. Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)

    Article • CPT Pharmacometrics & Systems Pharmacology, July 2017, Wiley

    Martin Posch

  118. Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov

    Article • Orphanet Journal of Rare Diseases, March 2017, Springer Science + Business Media

    Martin Posch, Catrin Tudur Smith

  119. “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?

    Article • Clinical Pharmacology & Therapeutics, October 2016, Wiley

    Martin Posch

  120. Estimation after blinded sample size reassessment

    Article • Statistical Methods in Medical Research, October 2016, SAGE Publications

    Martin Posch

  121. Optimizing Trial Designs for Targeted Therapies

    Article • PLOS One, September 2016, PLOS

    Martin Posch

  122. Multi-arm group sequential designs with a simultaneous stopping rule

    Article • Statistics in Medicine, August 2016, Wiley

    Martin Posch

  123. Directions for new developments on statistical design and analysis of small population group trials

    Article • Orphanet Journal of Rare Diseases, June 2016, Springer Science + Business Media

    Martin Posch

  124. Determination of the optimal sample size for a clinical trial accounting for the population size

    Article • Biometrical Journal, May 2016, Wiley

    Martin Posch

  125. Preface

    Article • Statistics in Medicine, March 2016, Wiley

    Martin Posch

  126. Fallback tests for co-primary endpoints

    Article • Statistics in Medicine, February 2016, Wiley

    Martin Posch

  127. Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions

    Article • Orphanet Journal of Rare Diseases, February 2016, Springer Science + Business Media

    Martin Posch

  128. Adaptive Designs for Clinical Trials with a Time to Event Endpoint

    Article • PLOS One, February 2016, PLOS

    Martin Posch

  129. Evidence, eminence and extrapolation

    Article • Statistics in Medicine, January 2016, Wiley

    Martin Posch

  130. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels

    Article • Statistics in Medicine, December 2015, Wiley

    Martin Posch

  131. Preoperative abnormalities in serum sodium concentrations are associated with higher in-hospital mortality in patients undergoing major surgery

    Article • British Journal of Anaesthesia, December 2015, Oxford University Press (OUP)

    Martin Posch, Eric Hoste

  132. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review

    Article • Journal of Biopharmaceutical Statistics, September 2015, Taylor & Francis

    Martin Posch

  133. Decision-theoretic designs for small trials and pilot studies: A review

    Article • Statistical Methods in Medical Research, June 2015, SAGE Publications

    Martin Posch

  134. Sample size reassessment for a two-stage design controlling the false discovery rate

    Article • Statistical Applications in Genetics and Molecular Biology, January 2015, De Gruyter

    Martin Posch

  135. MCP2013 - 8th International Conference on Multiple Comparison Procedures

    Article • Biometrical Journal, January 2015, Wiley

    Martin Posch

  136. Adaptive designs for subpopulation analysis optimizing utility functions

    Article • Biometrical Journal, November 2014, Wiley

    Martin Posch

  137. Adaptive graph-based multiple testing procedures

    Article • Pharmaceutical Statistics, October 2014, Wiley

    Martin Posch

  138. Flexible Designs

    Article • September 2014, Wiley

    Martin Posch

  139. Flexible Designs

    Article • September 2014, Wiley

    Martin Posch

  140. Bridging the gap: a review of dose investigations in paediatric investigation plans

    Article • British Journal of Clinical Pharmacology, September 2014, Wiley

    Martin Posch

  141. Connections between permutation andt-tests: relevance to adaptive methods

    Article • Statistics in Medicine, August 2014, Wiley

    Martin Posch

  142. Sharing clinical trial data on patient level: Opportunities and challenges

    Article • Biometrical Journal, June 2014, Wiley

    Martin Posch

  143. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients

    Article • British Journal of Anaesthesia, May 2014, Oxford University Press (OUP)

    Martin Posch

  144. Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union

    Article • Clinical Cancer Research, March 2014, American Association for Cancer Research (AACR)

    Martin Posch

  145. Morphine Decreases Clopidogrel Concentrations and Effects

    Article • Journal of the American College of Cardiology, February 2014, Elsevier

    Martin Posch

  146. Effect of intensive care after cardiac arrest on patient outcome: a database analysis

    Article • Critical Care, January 2014, Springer Science + Business Media

    Martin Posch

  147. Detection of epistatic effects with logic regression and a classical linear regression model

    Article • Statistical Applications in Genetics and Molecular Biology, January 2014, De Gruyter

    Martin Posch

  148. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency

    Article • Trials, January 2014, Springer Science + Business Media

    Martin Posch

  149. Adaptive Budgets in Clinical Trials

    Article • Statistics in Biopharmaceutical Research, November 2013, Taylor & Francis

    Martin Posch

  150. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs

    Article • Biometrika, October 2013, Oxford University Press (OUP)

    Martin Posch

  151. Flexible Designs

    Article • May 2013, Wiley

    Martin Posch

  152. MCP2011-The 7th international conference on multiple comparison procedures

    Article • Biometrical Journal, May 2013, Wiley

    Martin Posch

  153. Modeling and Simulation to Optimize the Design and Analysis of Confirmatory Trials, Characterize Risk-Benefit, and Support Label Claims

    Article • CPT Pharmacometrics & Systems Pharmacology, February 2013, Wiley

    Martin Posch

  154. Wideband UHF ISM-band transceiver supporting multichannel reception and DSSS modulation

    Article • February 2013, Institute of Electrical & Electronics Engineers (IEEE)

    Martin Posch

  155. Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude

    Article • Clinical Pharmacology & Therapeutics, January 2013, Nature

    Martin Posch

  156. Author's reply

    Article • Biometrical Journal, January 2013, Wiley

    Martin Posch

  157. Bridging the gap: a review of dose-investigation studies in paediatric investigation plans

    Article • Trials, January 2013, Springer Science + Business Media

    Martin Posch

  158. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients

    Article • Carcinogenesis, November 2012, Oxford University Press (OUP)

    Martin Posch

  159. Unplanned adaptations before breaking the blind

    Article • Statistics in Medicine, June 2012, Wiley

    Martin Posch

  160. Nanoscalic silver possesses broad-spectrum antimicrobial activities and exhibits fewer toxicological side effects than silver sulfadiazine

    Article • Nanomedicine Nanotechnology Biology and Medicine, May 2012, Elsevier

    Martin Posch

  161. False discovery rate control in two-stage designs

    Article • BMC Bioinformatics, January 2012, Springer Science + Business Media

    Martin Posch

  162. Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests

    Article • Biometrical Journal, August 2011, Wiley

    Martin Posch

  163. Impact of dental implant length on early failure rates: a meta-analysis of observational studies

    Article • Journal Of Clinical Periodontology, July 2011, Wiley

    Martin Posch

  164. Special Issue for Dealing with Multiplicity in Drug Development: Current State and New Directions – Guest Editors' Note

    Article • Journal of Biopharmaceutical Statistics, April 2011, Taylor & Francis

    Martin Posch

  165. Familywise Error Control in Multi-Armed Response-Adaptive Two-Stage Designs

    Article • Journal of Biopharmaceutical Statistics, April 2011, Taylor & Francis

    Martin Posch

  166. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim

    Article • Pharmaceutical Statistics, March 2011, Wiley

    Martin Posch

  167. Cross-platform comparison of microarray data using order restricted inference

    Article • Bioinformatics, February 2011, Oxford University Press (OUP)

    Martin Posch

  168. Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study

    Article • British Journal of Dermatology, December 2010, Wiley

    Martin Posch

  169. MCP2009 - 6th International Conference on Multiple Comparison Procedures

    Article • Biometrical Journal, December 2010, Wiley

    Martin Posch

  170. Availability of Mental Health Service Providers and Suicide Rates in Austria: A Nationwide Study

    Article • Psychiatric Services, December 2010, American Psychiatric Association

    Martin Posch

  171. Availability of Mental Health Service Providers and Suicide Rates in Austria: A Nationwide Study

    Article • Psychiatric Services, December 2010, American Psychiatric Association

    Martin Posch

  172. Early postpartum hysterectomy: incidence and risk factors

    Article • Acta Obstetricia Et Gynecologica Scandinavica, August 2010, Wiley

    Martin Posch

  173. Skateboarding Injuries in Vienna: Location, Frequency, and Severity

    Article • PM&R, July 2010, Elsevier

    Martin Posch

  174. On the ropivacaine-reducing effect of low-dose sufentanil in intrathecal labor analgesia

    Article • Acta Anaesthesiologica Scandinavica, June 2010, Wiley

    Martin Posch

  175. Post hoc power estimation in large-scale multiple testing problems

    Article • Bioinformatics, February 2010, Oxford University Press (OUP)

    Martin Posch

  176. Adaptive Designs and Confirmatory Hypothesis Testing

    Article • December 2009, Taylor & Francis

    Martin Posch

  177. Hunting for Significance With the False Discovery Rate

    Article • Journal of the American Statistical Association, June 2009, Taylor & Francis

    Martin Posch

  178. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology

    Article • Statistics in Medicine, May 2009, Wiley

    Martin Posch

  179. Adaptive designs for confirmatory clinical trials

    Article • Statistics in Medicine, April 2009, Wiley

    Martin Posch

  180. T cell senescence and contraction of T cell repertoire diversity in patients with chronic obstructive pulmonary disease

    Article • Clinical & Experimental Immunology, March 2009, Wiley

    Martin Posch

  181. Optimal choice of the number of treatments to be included in a clinical trial

    Article • Statistics in Medicine, February 2009, Wiley

    Martin Posch

  182. A graphical approach to sequentially rejective multiple test procedures

    Article • Statistics in Medicine, February 2009, Wiley

    Martin Posch

  183. Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double-blind study

    Article • Movement Disorders, January 2009, Wiley

    Martin Posch

  184. Selection and bias-Two hostile brothers

    Article • Statistics in Medicine, January 2009, Wiley

    Martin Posch

  185. Diagnostic accuracy and reliability of muscle strength and endurance measurements in patients with chronic low back pain

    Article • Journal of Rehabilitation Medicine, January 2009, Acta Dermato-Venereologica

    Martin Posch

  186. Correction

    Article • Statistics in Medicine, January 2009, Wiley

    Martin Posch

  187. Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial

    Article • Wiener klinische Wochenschrift, October 2008, Springer Science + Business Media

    Peter Ferenci, Martin Posch

  188. MCP2007 - 5th International Conference on Multiple Comparison Procedures

    Article • Biometrical Journal, October 2008, Wiley

    Martin Posch

  189. Optimized multi-stage designs controlling the false discovery or the family-wise error rate

    Article • Statistics in Medicine, September 2008, Wiley

    Martin Posch

  190. Exact Confidence Bounds Following Adaptive Group Sequential Tests

    Article • Biometrics, August 2008, Wiley

    Martin Posch

  191. A powerful multiple testing procedure improving the Bonferroni test

    Article • Journal of the American Statistical Association, March 2008, Taylor & Francis

    Martin Posch

  192. A Note on repeated p-values for group sequential designs

    Article • Biometrika, January 2008, Oxford University Press (OUP)

    Martin Posch

  193. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy

    Article • Journal of Rehabilitation Medicine, January 2008, Acta Dermato-Venereologica

    Martin Posch

  194. Adaptive Dunnett tests for treatment selection

    Article • Statistics in Medicine, January 2008, Wiley

    Martin Posch

  195. Flexible Designs

    Article • December 2007, Wiley

    Martin Posch

  196. Vergleichende Analyse der Messwertergebnisse von zwei Dynamometern zur Messung der isokinetischen Kraft der kniegelenksbewegenden Muskulatur

    Article • Physikalische Medizin Rehabilitationsmedizin Kurortmedizin, December 2007, Thieme Publishing Group

    Martin Posch

  197. The scientific work of Peter Bauer

    Article • Biometrical Journal, October 2007, Wiley

    Martin Posch

  198. Physiotherapy-Based Rehabilitation Following Disc Herniation Operation

    Article • Spine, September 2007, Wolters Kluwer Health

    Martin Posch

  199. Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans

    Article • Critical Care Medicine, August 2007, Wolters Kluwer Health

    Martin Posch

  200. Elevated levels of interleukin-1?-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction

    Article • European Journal of Clinical Investigation, May 2007, Wiley

    Martin Posch

  201. Repeated confidence intervals for adaptive group sequential trials

    Article • Statistics in Medicine, January 2007, Wiley

    Martin Posch

  202. Flexible Designs

    Article • August 2006, Wiley

    Martin Posch

  203. Clinical Features, Classification and Prognosis of Migraine and Tension-Type Headache in Children and Adolescents: A Long-Term Follow-Up Study

    Article • Cephalalgia, July 2006, SAGE Publications

    Martin Posch

  204. Diuretic potential of energy drinks

    Article • Amino Acids, June 2006, Springer Science + Business Media

    Martin Posch

  205. On the efficiency of adaptive designs for flexible interim decisions in clinical trials

    Article • Journal of Statistical Planning and Inference, June 2006, Elsevier

    Martin Posch

  206. Implant survival in mandibles of irradiated oral cancer patients

    Article • Clinical Oral Implants Research, June 2006, Wiley

    Martin Posch

  207. Flexible Designs

    Article • December 2005, Wiley

    Martin Posch

  208. Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial Comparing Adjuvant Interferon Alfa and Isotretinoin With Interferon Alfa Alone in Stage IIA and IIB Melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group

    Article • Journal of Clinical Oncology, October 2005, American Society of Clinical Oncology (ASCO)

    Professor H. Peter Soyer, Martin Posch

  209. Attainability of boundary points under reinforcement learning

    Article • Games and Economic Behavior, October 2005, Elsevier

    Martin Posch

  210. Two-stage designs for experiments with a large number of hypotheses

    Article • Bioinformatics, August 2005, Oxford University Press (OUP)

    Martin Posch

  211. Übersetzung und psychometrische Austestung des Western-Ontario-Rotator-Cuff-Index (WORC) für den Gebrauch in deutscher Sprache

    Article • Zeitschrift für Orthopädie und ihre Grenzgebiete, August 2005, Thieme Publishing Group

    Martin Posch

  212. Correlations between Self-Rated Fatigue with Quality of Life, and Social Participation in Viennese Outpatients Suffering from Advanced Cancer During Palliative Chemotherapy

    Article • Physikalische Medizin Rehabilitationsmedizin Kurortmedizin, August 2005, Thieme Publishing Group

    Martin Posch

  213. Übersetzung und psychometrische Austestung des Rotator Cuff Quality-of-Life Measure (RC-QOL) für den Gebrauch im deutschen Sprachraum

    Article • Zeitschrift für Rheumatologie, April 2005, Springer Science + Business Media

    Martin Posch

  214. Testing and estimation in flexible group sequential designs with adaptive treatment selection

    Article • Statistics in Medicine, January 2005, Wiley

    Martin Posch

  215. Long-term implant survival in the grafted maxilla: results of a 12-year retrospective study

    Article • Clinical Oral Implants Research, December 2004, Wiley

    Martin Posch

  216. The German version of the Oxford shoulder score?cross-cultural adaptation and validation

    Article • Archives of Orthopaedic and Traumatic Surgery, August 2004, Springer Science + Business Media

    Martin Posch

  217. Conditional Rejection Probabilities of Student'st-test and Design Adaptations

    Article • Biometrical Journal, August 2004, Wiley

    Martin Posch

  218. HSP-72 Expression in Pre-Transplant Donor Kidney Biopsies and Post-Transplant Outcome

    Article • Transplantation, July 2004, Wolters Kluwer Health

    Martin Posch

  219. Rehabilitation of the severely atrophied maxilla by horseshoe Le Fort I osteotomy (HLFO)

    Article • Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, June 2004, Elsevier

    Martin Posch

  220. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.-H. Müller,Statistics in Medicine 2001;20: 3741–3751

    Article • Statistics in Medicine, January 2004, Wiley

    Martin Posch

  221. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy

    Article • Supportive Care in Cancer, September 2003, Springer Science + Business Media

    Martin Posch

  222. Muscle Fatigue and Fatigue-Related Biomechanical Changes During a Cyclic Lifting Task

    Article • Spine, August 2003, Wolters Kluwer Health

    Martin Posch

  223. Sequential Tests for Noninferiority and Superiority

    Article • Biometrics, March 2003, Wiley

    Martin Posch

  224. Factors That Influence the Duration of Splint Wear in Peripheral Nerve Lesions

    Article • American Journal of Physical Medicine & Rehabilitation, February 2003, Wolters Kluwer Health

    Martin Posch

  225. Impact of Pneumococcal Vaccination on Morbidity and Mortality of Geriatric Patients: A Case-Controlled Study

    Article • Gerontology, January 2003, Karger Publishers

    Martin Posch

  226. Issues in designing flexible trials

    Article • Statistics in Medicine, January 2003, Wiley

    Martin Posch

  227. Statistical Methods for Clinical Trials. M. X. Norleans, Marcel Dekker, New York, 2001. No. of pages: 257. ISBN 0-8247-0467-3

    Article • Statistics in Medicine, January 2003, Wiley

    Martin Posch

  228. Recursive Combination Tests

    Article • Journal of the American Statistical Association, March 2002, Taylor & Francis

    Martin Posch

  229. The SCARF Osteotomy for the Correction of Hallux Valgus Deformities

    Article • Foot & Ankle International, March 2002, SAGE Publications

    Martin Posch

  230. Short segment stimulation of the anterior transposed ulnar nerve at the elbow

    Article • Archives of Physical Medicine and Rehabilitation, September 2001, Elsevier

    Martin Posch

  231. Multiple Testing for Identifying Effective and Safe Treatments

    Article • Biometrical Journal, September 2001, Wiley

    Martin Posch

  232. CROSS-CULTURAL ADAPTATION OF THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOR GERMAN-SPEAKING PATIENTS

    Article • Journal of Rehabilitation Medicine, July 2001, Taylor & Francis

    Martin Posch

  233. Flexible Two-Stage Designs: An Overview

    Article • Methods of Information in Medicine, January 2001, Thieme Publishing Group

    Martin Posch

  234. Interim Analysis and Sample Size Reassessment

    Article • Biometrics, December 2000, Wiley

    Martin Posch

  235. Load-dependence of fatigue related changes in tremor around 10 Hz

    Article • Clinical Neurophysiology, January 2000, Elsevier

    Martin Posch

  236. Adaptive Two Stage Designs and the Conditional Error Function

    Article • Biometrical Journal, October 1999, Wiley

    Martin Posch

  237. The efficiency of adapting aspiration levels

    Article • Proceedings of the Royal Society B Biological Sciences, July 1999, Royal Society Publishing

    Martin Posch

  238. Win–Stay, Lose–Shift Strategies for Repeated Games—Memory Length, Aspiration Levels and Noise

    Article • Journal of Theoretical Biology, May 1999, Elsevier

    Martin Posch

  239. Cycling in a stochastic learning algorithm for normal form games

    Article • Journal of Evolutionary Economics, June 1997, Springer Science + Business Media

    Martin Posch